Headline
The latest stories from AHA Today.
The rate of hospital-onset methicillin-resistant staphylococcus aureus bloodstream infections declined 17.1 percent per year between 2005 and 2012, but did not change significantly between 2013 and 2016.
The Senate Health, Education, Labor and Pensions Committee today held a hearing on vaccine-preventable diseases and the importance of vaccination to preventing measles and other disease outbreaks. After eliminating measles in 2000, the United States reported 372 measles cases last year and has…
Food and Drug Administration Commissioner Scott Gottlieb, M.D., announced that he will step down in about a month.
Five hospitals and five payers are participating in the first year of the Pennsylvania Rural Health Model, a multi-payer global budget model for rural critical access and acute-care hospitals in the state.
The ongoing outbreak of Ebola virus disease in the Democratic Republic of Congo serves as a reminder for U.S. health care facilities to review their infection prevention and control processes to safely identify and manage patients with communicable infections.
A panel commissioned by the American Board of Medical Specialties to review the continuing certification process recently released a report on its findings and recommendations.
The AHA, along with Baxter International Foundation and the Health Research & Educational Trust, is accepting applications through April 5 for the 2019 Foster G. McGaw Prize.
The Food and Drug Administration’s draft guidance on blood glucose monitoring test systems for prescription point-of-care use would appropriately improve the safety and efficacy of the devices while recognizing their vital role in hospitals and health systems, AHA said in comments submitted…
The Centers for Medicare & Medicaid Services has released updated resources intended to clarify whether a hospital outreach laboratory qualifies as an “applicable laboratory” under the Medicare Clinical Laboratory Fee Schedule and detailing related requirements for collecting and reporting…
The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs.